Loading...
NervGen Pharma Corp.
NGENF•PNK
Healthcare
Biotechnology
$2.58
$-0.12(-4.44%)
NervGen Pharma Corp. (NGENF) Financial Performance & Income Statement Overview
Review NervGen Pharma Corp.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-40.25%
↓ 40.25%
Net Income Growth
-7.25%
↓ 7.25%
Operating Cash Flow Growth
-49.09%
↓ 49.09%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-399.62%
↓ 399.62%
ROIC
-866.20%
↓ 866.20%
NervGen Pharma Corp. (NGENF) Income Statement & Financial Overview
Review NervGen Pharma Corp.'s (NGENF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $15028.00 | $38306.00 |
| Gross Profit | $0.00 | $0.00 | -$15028.00 | -$38306.00 |
| Gross Profit Ratio | ||||
| R&D Expenses | $4.59M | $4.36M | $3.80M | $3.00M |
| SG&A Expenses | $2.21M | $2.79M | $2.20M | $2.00M |
| Operating Expenses | $6.81M | $7.16M | $5.99M | $5.00M |
| Total Costs & Expenses | $6.81M | $7.16M | $6.000M | $5.00M |
| Interest Income | $171110.00 | $243679.00 | $294879.00 | $102949.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $15810.00 | $14652.00 | $15029.00 | $38306.00 |
| EBITDA | -$6.79M | -$7.14M | -$5.99M | -$4.95M |
| EBITDA Ratio | ||||
| Operating Income | -$6.81M | -$7.16M | -$6.000M | -$5.00M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | -$1.80M | $1.93M | -$1.83M | $2.62M |
| Income Before Tax | -$8.61M | -$5.23M | -$7.83M | -$2.35M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $2.30M |
| Net Income | -$8.61M | -$5.23M | -$7.83M | -$2.30M |
| Net Income Ratio | ||||
| EPS | -$0.12 | -$0.07 | -$0.11 | -$0.04 |
| Diluted EPS | -$0.12 | -$0.07 | -$0.11 | -$0.04 |
| Weighted Avg Shares Outstanding | $70.07M | $70.07M | $69.95M | $60.21M |
| Weighted Avg Shares Outstanding (Diluted) | $70.07M | $70.07M | $69.95M | $60.21M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan